Celgene to Pay $280 Million to Settle Fraud Suit Over Cancer Drugs

Photo of Celgene to Pay $280 Million to Settle Fraud Suit Over Cancer Drugs
Facebook
VKontakte
share_fav

The lawsuit accused the pharmaceutical company of marketing Thalomid and Revlimid for unapproved use on a broader range of cancers.

view The New York Times: Health
#whistle-blowers
#drugs pharmaceuticals
#suits and litigation civil
#thalidomide drug
#celgene corporation